by Raynovich Rod | Dec 11, 2022 | 2024 Rayno Biopharmaceuticals Portfolio
Update-2 Powell Reiterates Need To Fight Inflation The FED raised rates 50 bpts and Powell said more rate increases are coming, ( but aren’t we getting close to the top?). Stocks ended lower,NAZ down 0.75%, with gyrations in last 30 minute of trading. It was...
by Raynovich Rod | Dec 9, 2019 | Biopharmaceuticals, Macro
Update-1 …12/12/19…China Deal Announcement Boosts Dow S&P and NASDAQ. IBB up 0.68%, XBI up 0.58%, XLV up 0.93%. Large cap leaders: ABBV ALXN BMY, Chips, energy, financials strong; real estate weak. 10 year yield moves up to 1.894% =========== Early...
by Raynovich Rod | Nov 27, 2018 | Biopharmaceuticals
Update-2 December 3 …Our Top Pick TSRO is up 58% on GSK Buyout We recommended Tesaro (TSRO) at $34 and it paid off today with a ~$5.1B buyout by GlaxoSmith Kline! Year End Rally Intact with XBI up over 3% to $84 handle, ====== Update-1 December 1… NASDAQ...
by Raynovich Rod | Dec 7, 2017 | Biopharmaceuticals
Update 12/12/17 Biotech Rally Stalls at Resistance Celgene (CELG) holds $109. Mid-caps red especially INCY PTLA RDUS. Mixed market on low volume. Alexion (ALXN) trying to bounce. =============== Update 12/10/17 Can the biotech rally continue this week with ASH news?...